Tissue Programmed Hydrogels Functionalized with GDNF Improve Human Neural Grafts in Parkinson's Disease

被引:21
|
作者
Hunt, Cameron P. J. [1 ]
Penna, Vanessa [1 ]
Gantner, Carlos W. [1 ]
Moriarty, Niamh [1 ]
Wang, Yi [2 ,3 ]
Franks, Stephanie [2 ,3 ]
Ermine, Charlotte M. [1 ]
de Luzy, Isabelle R. [1 ]
Pavan, Chiara [1 ]
Long, Benjamin M. [4 ]
Williams, Richard J. [5 ]
Thompson, Lachlan H. [1 ]
Nisbet, David R. [2 ,3 ,6 ,7 ]
Parish, Clare L. [1 ]
机构
[1] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3052, Australia
[2] Australian Natl Univ, Res Sch Chem, Lab Adv Biomat, Canberra, ACT 2601, Australia
[3] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia
[4] Federat Univ, Sch Hlth & Life Sci, Mt Helen, Vic 3353, Australia
[5] Deakin Univ, Sch Med, Ctr Mol & Med Res, Waurn Ponds, Vic 3216, Australia
[6] Univ Melbourne, Graeme Clark Inst, Fac Engn & Informat Technol, Melbourne, Australia
[7] Univ Melbourne, Fac Med Dent & Hlth Serv, Melbourne, Australia
基金
澳大利亚国家健康与医学研究理事会; 英国医学研究理事会; 欧盟地平线“2020”;
关键词
biomaterials; dopamine; glial cell line-derived neurotrophic factor; hydrogels; laminin; Parkinson's disease; self-assembling peptides; stem cells; transplantation; MIDBRAIN DOPAMINE NEURONS; STEM-CELL; NEUROTROPHIC FACTOR; PROGENITOR CELLS; RAT MODEL; TRANSPLANTS; SCAFFOLDS; SURVIVAL; GROWTH; INTEGRATION;
D O I
10.1002/adfm.202105301
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The survival and synaptic integration of transplanted dopaminergic (DA) progenitors are essential for ameliorating motor symptoms in Parkinson's disease (PD). Human pluripotent stem cell (hPSC)-derived DA progenitors are, however, exposed to numerous stressors prior to, and during, implantation that result in poor survival. Additionally, hPSC-derived grafts show inferior plasticity compared to fetal tissue grafts. These observations suggest that a more conducive host environment may improve graft outcomes. Here, tissue-specific support to DA progenitor grafts is provided with a fully characterized self-assembling peptide hydrogel. This biomimetic hydrogel matrix is programmed to support DA progenitors by i) including a laminin epitope within the matrix; and ii) shear encapsulating glial cell line-derived neurotrophic factor (GDNF) to ensure its sustained delivery. The biocompatible hydrogel biased a 51% increase in A9 neuron specification-a subpopulation of DA neurons critical for motor function. The sustained delivery of GDNF induced a 2.7-fold increase in DA neurons and enhanced graft plasticity, resulting in significant improvements in motor deficits at 6 months. These findings highlight the therapeutic benefit of stepwise customization of tissue-specific hydrogels to improve the physical and trophic support of human PSC-derived neural transplants, resulting in improved standardization, predictability and functional efficacy of grafts for PD.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands
    Kirik, Deniz
    Cederfjall, Erik
    Halliday, Glenda
    Petersen, Asa
    NEUROBIOLOGY OF DISEASE, 2017, 97 : 179 - 188
  • [32] RNA-Seq and Histological Characterization of Human Peripheral Nerve Tissue for Use in Brain Grafts for the Treatment of Parkinson's Disease
    Welleford, A. S.
    van Horne, C. G.
    Quintero, J. E.
    Blalock, E. M.
    Stanford, J. A.
    Shapiro, S. M.
    Riordan, S. M.
    Gerhardt, G. A.
    CELL TRANSPLANTATION, 2018, 27 (04) : 719 - 719
  • [33] IMMATURE NEURAL TISSUE GRAFTS IN PARKINSONS-DISEASE
    WIDNER, H
    ACTA NEUROLOGICA SCANDINAVICA, 1993, 87 : 43 - 45
  • [34] Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease
    Brundin, P
    Pogarell, O
    Hagell, P
    Piccini, P
    Widner, H
    Schrag, A
    Kupsch, A
    Crabb, L
    Odin, P
    Gustavii, B
    Björklund, A
    Brooks, DJ
    Marsden, CD
    Oertel, WH
    Quinn, NP
    Rehncrona, S
    Lindvall, O
    BRAIN, 2000, 123 : 1380 - 1390
  • [35] Combination therapy using GDNF and cell transplant in Parkinson's disease
    Xiao, Bin
    Zhang, Su-Chun
    Tan, Eng-King
    MOLECULAR NEURODEGENERATION, 2022, 17 (01)
  • [36] GDNF signaling in subjects with minimal motor deficits and Parkinson?s disease
    Chu, Yaping
    Kordower, Jeffrey H.
    NEUROBIOLOGY OF DISEASE, 2021, 153
  • [37] AAV2-GDNF Gene Therapy for Parkinson's Disease
    Ram, Sharona Even
    Galun, Eithan
    HUMAN GENE THERAPY, 2009, 20 (05) : 430 - 431
  • [38] GDNF Family Ligands: A Potential Future for Parkinson's Disease Therapy
    Mickiewicz, Amanda L.
    Kordower, Jeffrey H.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2011, 10 (06) : 703 - 711
  • [39] GDNF treatment in Parkinson's disease: time for controlled clinical trials?
    Brundin, P
    BRAIN, 2002, 125 : 2149 - 2151
  • [40] GDNF in Parkinson's disease: The perils of post-hoc power
    Matcham, James
    McDermott, Michael P.
    Lang, Anthony E.
    JOURNAL OF NEUROSCIENCE METHODS, 2007, 163 (02) : 193 - 196